Recurrent Soft Tissue Sarcoma Recruiting Phase 1 / 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0105100 (Recurrent Soft Tissue Sarcoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03338959Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue SarcomaTreatment